Akari Therapeutics (AKTX) Other Non-Current Liabilities (2014 - 2025)

Akari Therapeutics has disclosed Other Non-Current Liabilities across 6 years of filings, most recently posting $230000.0 for Q4 2025.

• Other Non-Current Liabilities for Q4 2025 came in at $230000.0, down 39.95% year-over-year; the trailing twelve-month figure through Dec 2025 was $230000.0 (down 39.95% YoY), and the FY2025 annual result was $230000.0, down 39.95% from the prior year.
• Other Non-Current Liabilities came in at $230000.0 for Q4 2025 at Akari Therapeutics, up from $100000.0 in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $383000.0 in Q4 2024 to a low of $100000.0 in Q4 2022.
• The 4-year median for Other Non-Current Liabilities is $100000.0 (2022), against an average of $160700.0.
• Across the five-year window, Other Non-Current Liabilities surged 283.0% in 2024 and plunged 39.95% in 2025, its largest moves.
• Akari Therapeutics' Other Non-Current Liabilities stood at $100000.0 in 2022, then changed by 0.0% to $100000.0 in 2023, then soared by 283.0% to $383000.0 in 2024, then slumped by 39.95% to $230000.0 in 2025.
• The last three Other Non-Current Liabilities figures came in at $230000.0 (Q4 2025), $100000.0 (Q3 2025), and $128000.0 (Q2 2025), per Business Quant data.